<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1627">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094300</url>
  </required_header>
  <id_info>
    <org_study_id>05-622</org_study_id>
    <nct_id>NCT02094300</nct_id>
  </id_info>
  <brief_title>Zenith® Dissection Endovascular System</brief_title>
  <acronym>STABLE I</acronym>
  <official_title>Zenith® Dissection Endovascular System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Zenith® Dissection Clinical Trial is a clinical trial approved by US FDA to study the
      safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of
      patients with aortic dissection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with major adverse events</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Aortic Dissection</condition>
  <arm_group>
    <arm_group_label>Endovascular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zenith® Dissection Endovascular Graft</intervention_name>
    <description>Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.</description>
    <arm_group_label>Endovascular</arm_group_label>
    <other_name>Endovascular graft</other_name>
    <other_name>Stent-graft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Branch vessel obstruction/compromise

          -  Peri-aortic effusion/hematoma

          -  Resistant hypertension

          -  Persistent pain/symptoms

          -  Transaortic growth &gt;5 mm within 3 months

          -  Transaortic diameter &gt;40 mm.

        Exclusion Criteria:

          -  Age &lt;18 years;

          -  Other medical condition (e.g., cancer, congestive heart failure) that may cause the
             patient to be non-compliant with the protocol, confound the results, or is associated
             with limited life expectancy (i.e., less than 2 years)

          -  Pregnant, breast-feeding, or planning on becoming pregnant within 24 months;

          -  Unwilling or unable to comply with the follow-up schedule

          -  Inability or refusal to give informed consent

          -  Simultaneously participating in another investigative device or drug study.  (The
             patient must have completed the primary endpoint of any previous study at least 30
             days prior to enrollment in this study.)

          -  Additional medical restrictions as specified in the Clinical Investigation Plan, or

          -  Additional anatomical restrictions as specified in the Clinical Investigation Plan.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Lombardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cooper University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetss General Hospital</name>
      <address>
        <city>Boston,</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadephia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aorta</keyword>
  <keyword>Thoracic</keyword>
  <keyword>Aortic dissection</keyword>
  <keyword>Rupture</keyword>
  <keyword>Type B</keyword>
  <keyword>DeBakey type III</keyword>
  <keyword>Endovascular</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
